EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tsubota Laboratory's EBITDA for the
six
months ended in Mar. 2026 was 円-416.8 Mil. Tsubota Laboratory's Revenue for the
six
months ended in Mar. 2026 was 円97.2 Mil. Therefore, Tsubota Laboratory's EBITDA margin for the quarter that ended in Mar. 2026 was -428.62%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tsubota Laboratory EBITDA Margin % Related Terms
Tsubota Laboratory EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tsubota Laboratory's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4890 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Tsubota Laboratory's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsubota Laboratory EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tsubota Laboratory's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tsubota Laboratory's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsubota Laboratory (TSE:4890) has a EBITDA Margin % of -428.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tsubota Laboratory and its competitors. According to the industry distribution chart, Tsubota Laboratory ranks #739 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 90.6%.
Is Tsubota Laboratory's EBITDA Margin % too high?
Tsubota Laboratory's current EBITDA Margin % is -428.62%. Based on the distribution chart, Tsubota Laboratory ranks #739 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tsubota Laboratory has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tsubota Laboratory's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Tsubota Laboratory ranks #739 out of 816 companies for EBITDA Margin %. This places Tsubota Laboratory in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tsubota Laboratory and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsubota Laboratory's current EBITDA Margin % is -428.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsubota Laboratory stock overvalued right now?
Based on GuruFocus' analysis, Tsubota Laboratory (TSE:4890) is currently considered Significantly Overvalued. The stock's GF Value™ is 円83.95, compared to a current price of 円221.00 — trading 163.3% above its estimated fair value. The current EBITDA Margin % is -428.62%. Tsubota Laboratory's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tsubota Laboratory (TSE:4890), the current EBITDA Margin % is -428.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsubota Laboratory (TSE:4890) Overvalued in 2026?
Based on GuruFocus' analysis, Tsubota Laboratory stock appears to be overvalued.
The current stock price of 円221.00 is trading 163.3% above its estimated GF Value™ of 円83.95.
GuruFocus considers Tsubota Laboratory to be Significantly Overvalued.
Key valuation signals for TSE:4890:
EBITDA Margin %: -428.62%
GF Value™: 円83.95 vs. price of 円221.00 (163.3% above fair value)
No single metric tells the full story. See the TSE:4890 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
63GF Score
Get the complete analysis for TSE:4890
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4890 has been successfully added to your 
